Introduction of 1,3-diethyl-4,5-diphenyl-4,5-dihydro-1H-imidazol-2-ylidene as new ligand for the design of antitumor-active (NHC)gold(I) complexes: An approach to reduce ligand scrambling and to increase tumor cell selectivity